eClinical technology company, Axiom Real-Time Metrics, will be recapitalized by Great Point Partners to provide eClinical solutions to increase service offerings for Phase I-III clinical trials.
Mispro is expanding its vivarium service network with the opening of its fifth facility, an 18,000 square foot facility in Broad Hollow Bioscience Park, NY.
Lonza will provide manufacturing for Alector’s Phase I drug candidates for neurodegenerative diseases from its Switzerland site, which is expected to be operational by mid-2020.
Increasingly concerned with the potential for cyber attacks at third-party vendors, pharma looks to gain visibility into supplier performance, says industry expert after the recent breach at Charles River.
On the path to first-in-human clinical trials one of the main challenges is “velocity, ensuring rapid delivery of delivered drug product into the clinical program,” says CDMO.
Oncology and immunotherapies are the top two indications for global clinical research – and are driving a significant growth in the market demand for HPAPIs, says Patheon executive.
Sharp’s clinical services center is approved by the MHRA and now ready to offer services for serialization and trial management while reducing carbon footprint with the addition of solar panel systems.
Using automated chain-of-custody systems can save study sponsors and CROs a minimum of $1.3m per clinical trial in operating costs, according to a recent report from Almac.
Catalent Pharma Solutions has opened its new, 30,000-square-foot Shanghai, China-based clinical supply facility, which is expected to employ up to 100.
Bringing together the food industry’s know-how and pharma’s manufacturing expertise, the new joint venture from Lonza and Chr. Hansen is positioned to pioneer the live biotherapeutic products space – addressing medical needs not met with ‘conventional’...
With 70% of its customers in North America and demand increasing, the UK-based CDMO Sterling Pharma Solutions has acquired CiVentiChem’s US facility in Cary, North Carolina.
Cell One Partners formally launches its consulting services and aims to be a long-term partner to its clients, supporting the development of cell and gene therapies – a market which raised more than $13.3bn in 2018.
